AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents mixed signals. The company has a substantial cash reserve but experienced a decrease due to investments. The focus on pipeline development is promising, but the lack of efficacy data and unclear guidance in the Q&A section raises concerns. The potential for blockbuster treatments is a positive, but the absence of immediate catalysts and management's evasive responses temper enthusiasm. Overall, the sentiment is neutral.
Key Financial Performance
Revenue Revenue for the quarter was around $8 million compared to a total revenue of approximately $4 million in the same quarter of 2025, representing a 100% increase year-over-year. This increase was mostly due to research fees.
Research and Development Expenses Research and development expenses for the quarter were approximately $47 million, approximately $4 million more than last year, reflecting an increase of about 9.3% year-over-year. This expense reflects the focus of investment in internal programs.
Sales, General and Administration Expenses Sales, general and administration expenses were approximately $12 million compared to roughly $19 million last year, representing a decrease of greater than 35% year-over-year. This decrease relates to the conclusion of intellectual property litigation and changes in teams following the focus on the internal pipeline.
Net Loss Net loss for the first quarter of 2026 was roughly $43 million compared to a loss of about $46 million a year earlier, representing a slight improvement in losses year-over-year. This improvement is attributed to reduced SG&A expenses.
Cash and Equivalents Operating activities for the first quarter used approximately $34 million in cash and equivalents. Excluding marketable securities and all other investment activities, it amounted to only $3 million in the quarter. The company finished the quarter with $531 million of cash, cash equivalents, and marketable securities, a $30 million decrease from the previous quarter. This reflects the substantial completion of large investments in facilities and manufacturing capabilities in 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ABCL635 advancement: ABCL635 has moved into Phase II testing, with interim Phase I data showing it as a potential first-in-class antibody medicine for nonhormonal treatment of moderate to severe hot flashes associated with menopause. The U.S. market for non-hormonal VMS treatments is estimated at $6 billion annually.
ABCL575 progress: Top line Phase I readout for ABCL575, a potential best-in-class OX40 ligand antagonist, is expected in Q4 2026. The company plans to partner it after Phase I.
Pipeline expansion: Two additional programs, ABCL688 and ABCL386, are expected to enter clinical development by 2027. A fifth development candidate is on track for selection in the first half of 2026.
Market opportunity for ABCL635: The U.S. market for non-hormonal VMS treatments is estimated at $6 billion annually, with potential for broader use in cancer treatment-induced VMS.
Financial position: AbCellera has $530 million in cash and equivalents, $125 million in committed government funding, and $428 million in short-term marketable securities, providing liquidity for at least the next 3 years of pipeline investments.
Revenue and expenses: Q1 2026 revenue was $8 million, primarily from research fees, while R&D expenses were $47 million, reflecting focus on internal programs. SG&A expenses decreased by over 35% to $12 million due to litigation conclusion and team changes.
Focus on internal pipeline: The company is prioritizing internal programs over external research collaborations, as reflected in reduced research fee revenue and increased R&D expenses.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company acknowledges that its forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially. This includes potential regulatory hurdles that could impact the approval and progress of their drug candidates.
Clinical Development Risks: The success of ABCL635 and other pipeline programs depends on the outcomes of clinical trials. Any unfavorable results in Phase II or subsequent trials could significantly impact the company's strategic objectives and financial performance.
Market Adoption Risks: While ABCL635 targets a significant unmet need in women's health, its market adoption depends on its ability to demonstrate efficacy, safety, and convenience compared to existing treatments. Failure to achieve these could limit its market potential.
Financial Risks: The company reported a net loss of $43 million for Q1 2026 and continues to invest heavily in R&D. Sustained losses could impact its ability to fund future pipeline investments.
Competitive Risks: The company faces competition from existing small molecule NK3R antagonists and other treatments for vasomotor symptoms. This could limit its market share and revenue potential.
Pipeline Execution Risks: The company has ambitious goals to advance multiple programs into clinical stages by 2027. Delays or failures in achieving these milestones could impact its strategic plans.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ABCL635 Phase II Study: The company anticipates top-line results for the Phase II study of ABCL635, a potential first-in-class antibody medicine for nonhormonal treatment of moderate to severe hot flashes, in Q3 2026. The study is a randomized, double-blind, placebo-controlled multicenter study with approximately 80 patients. Success in this study would lead to late-stage clinical development and additional studies for VMS caused by cancer treatments.
ABCL575 Phase I Study: Top-line Phase I readout for ABCL575, a potential best-in-class OX40 ligand antagonist, is expected in Q4 2026. The company plans to complete Phase I studies before partnering the program.
Pipeline Expansion: The company aims to have up to three additional clinical-stage programs by the end of 2027, including ABCL688 and ABCL386, which are expected to start clinical development in Phase I/II studies. A fifth development candidate is expected to be selected in the first half of 2026.
Financial Guidance: The company has approximately $530 million in cash and equivalents, with $125 million in committed government funding, providing sufficient liquidity to fund at least the next three years of pipeline investments.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is your opinion on whether small molecule antagonists are leaving efficacy on the table, and could better efficacy be displayed in the 4-week VMS severity and frequency data?
A:The study is focused on evaluating target engagement on NK3R in the infundibular nucleus, which is not a direct report on efficacy. The Phase II study will provide clarity in Q3. The goal is to achieve efficacy comparable to small molecules with a cleaner safety profile and convenient dosing. There is a strong scientific case for better efficacy, but further study is needed.
Q:Do you feel you will have done sufficient dose optimization work to move directly into a Phase III study in 2027?
A:The proof-of-concept Phase II readout will provide robust PK/PD data to assess efficacy over time. This data will help engage regulators for late-stage development. Regulators may request additional dose testing in Phase III, but it is not anticipated to be necessary.
Q:How could the strong testosterone data translate into benefit for patients with VMS, and what is the potential for expanding indications into oncology?
A:There is a correlation between target engagement (testosterone suppression) and efficacy based on small molecule data, but this may not fully translate to antibodies. The program is focused on VMS associated with menopause and induced menopause from cancer treatments, which can cause severe symptoms. There is potential for benefit in oncology-related cases like breast and prostate cancer treatments.
Q:Why was the Phase II dose of 600 mg selected, and is there a risk it fails to maintain testosterone suppression at the end of the 4-week window?
A:The 600 mg dose approximates the predicted Cmax at steady state for the 300 mg regimen. PK data and sustained target engagement suggest 4 weeks is a good evaluation period. The AE rate at 600 mg is reassuring, and the dose is compatible with commercial auto-injectors.
Q:What was the rationale for capping the multiple ascending dose trial at 600 mg, and will data from this trial be shared before the Phase II efficacy readout?
A:The 600 mg cap was chosen to provide a safety window and exposures appropriate for late-stage development, not due to safety signals. Data from the multiple ascending dose trial will not be shared before the Phase II readout.
Q:What is the goal for testosterone reduction and dosing window, and is there optionality for extending the dosing window beyond 4 weeks?
A:The goal is prolonged, stable target engagement over the dosing period. A 4-week dosing period is deemed appropriate, but the 12-week follow-up in Phase II will provide more insights. There is potential for adjustments based on efficacy data.
Q:Do you have a sense of which preclinical asset (688 or 386) will enter clinical trials first?
A:Both assets are advancing well, but no decision has been made yet on which will enter clinical trials first.
Q:Have you collected any PRO data from postmenopausal women in the SAD or MAD portions, and are there any trends in VMS symptoms?
A:Efficacy data is not collected in the SAD or MAD portions as they do not have the same eligibility criteria or diaries as Phase II. Robust answers are expected from Phase II in Q3.
Q:What kind of PD impact is expected with chronic dosing of 600 mg, and is there room for higher PD engagement?
A:The 600, 300, and 900 mg doses show robust target engagement. Higher PD engagement is not anticipated to be necessary. A loading dose strategy is being considered to treat VMS quickly.
Q:What was observed in the placebo group regarding testosterone levels, and how is testosterone measured in the study?
A:Placebo group testosterone levels showed no appreciable effects. Testosterone is measured at the same time each day, typically in the morning.
Q:What explains the onset of action differences between the antibody and small molecules like fezolinetant?
A:The difference is due to the time it takes for a subcutaneously administered antibody to reach Cmax compared to an oral small molecule, which achieves Cmax relatively quickly.
Q:Review of Unclear Management Responses
A:Management avoided providing direct answers to questions about the potential for extending the dosing window beyond 4 weeks and the specific timeline for preclinical assets 688 and 386 entering clinical trials. Additionally, they did not provide clarity on whether data from the multiple ascending dose trial would be shared before the Phase II readout.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
KNDy neuron
NKR engagement
Participants
Phase II
ascending dose
cancer treatment
dos milligram
dose cohort
dose portion
dose study
effect
fezolinetant
function
hormone
hour
hypothalamus
liver
men woman
panel
participant
patient
period
pharmacokinetics
placebo group
portion study
potential
testing
testosterone level
testosterone suppression
week
ABCL Transcript
AbCellera Biologics Inc. (ABCL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-14
AbCellera Biologics Inc. (ABCL) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call summary presents mixed signals. The company has a substantial cash reserve but experienced a decrease due to investments. The focus on pipeline development is promising, but the lack of efficacy data and unclear guidance in the Q&A section raises concerns. The potential for blockbuster treatments is a positive, but the absence of immediate catalysts and management's evasive responses temper enthusiasm. Overall, the sentiment is neutral.
AbCellera Biologics Inc. (ABCL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Neutral3-6
AbCellera Biologics Inc. (ABCL) Q4 2025 Earnings Call Transcript
Unknown2-24
The earnings call presents mixed signals. While there is significant liquidity and completion of capital expenditures, revenue trends are declining, and R&D expenses have increased. The Q&A reveals potential in ABCL575 and ABCL635 but lacks specifics on timelines and patient numbers. Revenue increase from patent settlements is positive, but the net loss remains significant. The absence of guidance adjustments and unclear management responses contribute to a neutral sentiment.
ABCL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
